PTOSSING (7.6)
Approved for use through 07.15(07.12) (ME 965.75)
U.S. Palent and Trademak Office (U.S. DEPARTMENT OF COMMERCE
U.S. Palent and Trademak Office (U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of daughts a video. ONE soften creative

		STATEMENT UNDER 37 CFR 3.73(b)
		wner: Alan Drizen, et al.
Application	ent No : 90/011,847 / 5,897,880 Filed/Issue Date: August 4, 2011 / April 27, 1999	
Titled		L DRUG PREPARATIONS
GlycoBio	Sciences	Inc. , a Corporation
(Name of As	saignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
states the	atıtıs:	
1, 🔀	the assig	gnee of the entire right, title, and interest in;
2.	an assig (The ext	nee of loss than the entire right, title, and interest in ent (by percentage) of its ownership interest is
3	the assig	gnee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)
the patent	t applicatio	on/patent identified above, by virtue of either
Α 🗌	An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, or for which a copy therefore is attached.	
OR		
в. 🔀		of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
	1. From	Alan Drizen (Estate of Alan Drizen), et al. To: L.A.M. Pharmaceutical, Corp.
		The document was recorded in the United States Patent and Trudemark Office at Reel 027887 , Frame 0752 , or for which a copy thereof is attached
	2. From	: L.A.M. Pharmaceutical, Corp. To GlycoBioSciences Inc.
		The document was recorded in the United States Patent and Trademark Office at Reel 021561 Frame 0330 or for which a copy thereof is attached
	3. From:	
		The document was recorded in the United States Patent and Trademark Office at
		Reel . Frame . or for which a copy thereof is attached
	Addition	al documents in the chain of title are listed on a supplemental sheet(s).
As or o	required by	y 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, y is being, submitted for recordation pursuant to 37 CFR 3.11.
[NC	TE: A sep ordance va	earate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in kH-37 OFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302 081
The under	signed (wh	nopel title is supplied below) is authorized to act on behalf of the assignee
Sig	gnature	Apri 29,2012
Kevin Driz	en	President
Pri	nted or Ty	ped Name Title
Chile seelles effect	of Informatio	n is more and by 27 CCD 2 Years The state of the

This called not deformation in service by 37 OFTR 3.73b. The photometric increased in contract of continued to destine or retain is served by the public which is for like find by the USPTO to proceeds a recipionic Confidentiality is serviced by 48.15 SEC 12 and 37 CEPT 1.10 or 12 center of the contract of the total contract of the contract of the total contract of the total contract of the total contract of the contract of Commerce, P.O. Box 1450, Alexandria, VA. 22311-1460, DO MOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO Committee of the contract of the

If you need assistance in completing the form, cell 1-800-PTO-9199 and select option 2

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93.579) requires that you be given certain information in connection with your submission of the attacked form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that; (1) the general authority, for the collection of this information is 50 S.C. 2(b)(2); (2) furnishing of the information is liceled as voluntary, and (3) the principal purpose for which he information is used by the U.S. Patent and Trademark office of the principal purpose is which he information is used by the U.S. Patent and Trademark office of the principal purposes and/or examine your submission whether and rindemark office may not be able to process and/or examine your submission, whether and rindemark office may not be able to process and/or examine your submission, whether and rindemark office may not be able to process and/or examine your submission, whether and remarks office and the process and/or examine your submission, whether the patent is the submission of proceedings or

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (6 U.S.C. 552) and the Privacy Act (6 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
- A "record" in this system of records may be discissed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a confractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designer, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management pradices and programs, under authority of 44 U.S.C. 2904 and 2905, Such disclosure shall be made in accordance with the GSA regulations governing inspection of records rehis purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about Individual.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 36 U.S.C. 151. Further, a record may be disclosed, subject to the illinitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.